- The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS.
- What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism.
- Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated.
A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS, clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate.
Questions around this news
What does FDA approval of an IND application mean?
An Investigational New Drug application is a regulatory submission seeking authorization to test an experimental drug in people. FDA approval of an IND allows the proposed clinical investigation to proceed under applicable safeguards; it is not marketing authorization and does not establish that the drug is effective or safe for general use.
What is the purpose of a Phase 2 clinical trial?
Phase 2 trials generally study a treatment in people who have the condition it is intended to address. Researchers assess whether it shows signs of benefit and continue evaluating safety, often using a controlled study design. Moving into Phase 2 does not mean a treatment has been proven effective or approved for sale.
What does the release say about Lucid-MS?
The release identifies Lucid-MS as Quantum BioPharma’s lead compound and a candidate for multiple sclerosis. It says the FDA approved the company’s IND application, clearing the way for Phase 2 clinical testing. The release describes Lucid-MS as a proprietary treatment and says its mechanism sets it apart from most existing MS therapies.
What results did Lucid-MS show in Phase 1?
The release says Lucid-MS completed Phase 1 clinical trials and showed a favorable safety profile while being well tolerated. It does not provide trial size, specific safety findings, or evidence of effectiveness. The reported Phase 1 experience therefore describes tolerability and safety observations, not proof that Lucid-MS treats multiple sclerosis.
The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Terms explained
- Investigational New Drug (IND) application
- A regulatory submission seeking authorization to study an experimental drug in people. It is separate from approval to market the drug.
- Phase 1 clinical trial
- An early stage of human testing that primarily evaluates a treatment’s safety and how people tolerate it.
- Phase 2 clinical trial
- A stage of clinical testing that studies a treatment in people with the target condition, examining potential benefit while continuing to assess safety.
- Multiple sclerosis (MS)
- A disease in which the immune system damages the protective covering of nerve fibers in the brain and spinal cord, disrupting communication between them.
- Neurodegenerative disorder
- A condition involving progressive damage or loss of nerve cells, which can affect movement, thinking, or other functions.
SEC filings
Earlier from Quantum BioPharma
- Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
- Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
